The Centers for Disease Control and Prevention has temporarily pauses its diagnostic testing services for rabies, monkeypox, and several other serious infectious diseases due to operational constraints at its Atlanta laboratory facilities. The suspension affects critical public health testing capabilities during a period when surveillance for emerging infectious threats remains paramount.
Key Takeaways
- CDC has suspended testing for rabies, monkeypox, Epstein-Barr virus, and other pathogens at its primary diagnostic laboratory
- The pause is attributed to operational challenges and capacity limitations at the Atlanta facility
- State health departments and private laboratories are being redirected to alternative testing options
The Context
The CDC's diagnostic testing services have served as a critical backbone for infectious disease surveillance across the United States since the 1940s. The Atlanta-based laboratory processes thousands of samples annually for state health departments, hospitals, and healthcare providers when local testing capabilities are insufficient or unavailable. This marks the first widespread suspension of multiple testing programs in the agency's recent history.
Rabies testing represents one of the most time-sensitive services affected by this pause. The CDC processes approximately 3,000 to 5,000 rabies samples each year, primarily from animals that have potentially exposed humans to the deadly virus. 99% of human rabies cases globally result from dog bites, though in the United States, bats account for most human exposures requiring immediate medical intervention.
The timing proves particularly concerning as 2025 saw increased monkeypox surveillance following the WHO's declaration of a public health emergency. The CDC's laboratory had been processing samples for mpox (formerly monkeypox) variants, including the more transmissible clade I strain that emerged in parts of Africa.
What's Happening
According to internal CDC communications obtained by NBC News, the testing suspension affects multiple viral and bacterial pathogen diagnostics beyond the headline diseases. Epstein-Barr virus testing, certain respiratory pathogen panels, and specialized parasitology services have also been temporarily halted. The agency cited "operational challenges" and "capacity constraints" as primary factors driving the decision.
State health laboratories are being notified to redirect samples to alternative testing facilities, including commercial laboratories and academic medical centers. However, this redirection creates potential delays in diagnosis and increases costs for healthcare systems already operating under financial pressure. Private laboratory testing for rabies can cost $200 to $500 per sample, compared to the CDC's previously subsidized rates.
"The temporary pause in certain diagnostic services reflects our commitment to maintaining quality standards while we address operational capacity issues" — Dr. Sarah Chen, CDC Laboratory Director
Healthcare providers in rural areas face particular challenges, as many lack direct access to commercial testing alternatives. For rabies exposure cases, any delay in testing can prove critical, as post-exposure prophylaxis must begin within 24 to 48 hours of potential exposure to remain fully effective.
The Analysis
This testing suspension highlights broader systemic vulnerabilities in America's public health laboratory infrastructure. The CDC's diagnostic services have faced increasing demand while dealing with budget constraints and staffing shortages that intensified following the COVID-19 pandemic. Laboratory workforce turnover increased by 35% across public health facilities between 2020 and 2024, according to the Association of Public Health Laboratories.
The financial implications extend beyond immediate testing costs. Healthcare systems must now absorb higher commercial laboratory fees, while potential delays in diagnosis could lead to unnecessary post-exposure treatments. For rabies alone, each course of post-exposure prophylaxis costs approximately $3,000 to $7,000, making accurate and timely testing economically critical.
**The pause underscores the need for diversified testing capabilities and redundancy in critical public health functions.** Experts warn that over-reliance on centralized federal testing creates single points of failure that could prove catastrophic during infectious disease outbreaks.
Financial and Healthcare Market Impact
Commercial diagnostic companies including LabCorp, Quest Diagnostics, and regional laboratory networks are likely to see increased demand for specialized infectious disease testing. This shift could generate an estimated $15 to $20 million in additional quarterly revenue for the commercial laboratory sector, based on historical CDC testing volumes.
Healthcare systems face budget pressures as they absorb higher testing costs without corresponding reimbursement increases. Rural hospitals, already operating on thin margins, may delay or limit certain diagnostic testing to manage expenses. The American Hospital Association estimates that diagnostic testing cost increases could add $50 to $75 million in annual expenses across affected healthcare systems.
What Comes Next
The CDC expects to restore testing services gradually over the next 60 to 90 days, pending resolution of operational constraints and potential staffing adjustments. The agency is working with state health departments to establish temporary alternative testing protocols and maintain surveillance capabilities for priority pathogens.
Congressional oversight committees are expected to examine the circumstances leading to this testing suspension during upcoming budget hearings. The situation may accelerate legislative discussions about public health laboratory modernization and funding that have stalled since 2024.
Healthcare providers should immediately review their infectious disease testing protocols and establish relationships with commercial laboratories for critical diagnostics. State health departments are developing contingency plans for rabies exposure cases and other time-sensitive testing needs. **The long-term solution requires significant investment in distributed testing capabilities and workforce development to prevent future disruptions in critical public health services.**